Search
SOLACI Congress
HomeCONGRESS

CONGRESS

View Category
Coronary disease

Virtual ACC 2020 | PRECOMBAT: 10 Years for Surgery vs. Angioplasty in Left Main Coronary Artery Disease

After 10 years of follow-up, there were no significant differences in the rates of major adverse cardiovascular or...
solaci -
Learn More
Antiplatelet

Virtual ACC 2020 | TWILIGHT-COMPLEX: Ticagrelor Monotherapy in the Most “Dangerous” Angioplasties

The original TWILIGHT findings in more than 9000 patients who underwent angioplasty were presented last year at TCT...
solaci -
Learn More
Structural heart disease

Virtual ACC 2020 | First Results of Evolut in Low-Risk Bicuspid Valves

The initial results of this study presented “virtually” at the American College of Cardiology (ACC) 2020 Scientific...
solaci -
Learn More
Antiplatelet

Virtual ACC 2020 | TWILIGHT-DM: Ticagrelor Monotherapy in Diabetic Patients

In parallel to the TWILIGHT in patients with complex PCI, Dr. Angiolillo virtually presented the sub-study in...
solaci -
Learn More
Antithrombotic Anticoagulants

Virtual ACC 2020 | POPULAR TAVR: Post TAVR Anticoagulation without Clopidogrel?

In patients undergoing transcatheter aortic valve replacement (TAVR) that also required anticoagulation for another indication (mostly atrial...
solaci -
Learn More
STRUCTURAL HEART DISEASE

Virtual ACC 2020 | PARTNER 3: TAVR vs CABG in Low Risk at 2 Years

The 2-year outcomes in patients with severe aortic stenosis and low surgical risk continue to show a...
solaci -
Learn More
Antithrombotic Anticoagulants

Virtual ACC 2020 | Antidote for Life-Threatening Bleeding with New Anticoagulant Agents

Among patients hospitalized with life-threatening or uncontrolled bleeding under treatment with direct factor Xa inhibition, anticoagulation reversal with...
solaci -
Learn More
Chronic Ischemic cardiopathy

Virtual ACC 2020 | ISCHEMIA: Quality of Life, Not a Soft Endpoint

In the general study, an invasive strategy followed by revascularization (when necessary) vs. an initially conservative strategy...
solaci -
Learn More

SOLACI is the reference organization for Latin American cardiovascular interventionism.

Last News

AHA 2024 | VANISH2 Trial

Dr. Omar Tupayachi - 0
Cardiac defibrillator implants (CDIs) have been shown to improve survival in patients with ischemic cardiomyopathy and ventricular tachycardia (VT). However, approximately one third of...

AHA 2024 | SUMMIT

Dr. Omar Tupayachi - 0
It has been previously shown that the pharmacological treatment of obesity (semaglutide) can reduce cardiovascular events in patients with cardiac failure (CF) and preserved...

AHA 2024 – BPROAD

Dr. Omar Tupayachi - 0
Hypertension (elevated blood pressure, BP) is the most common comorbidity among diabetic patients and has been associated with higher cardiovascular risk, though as a...

Institutional News

Check out the best images of the El Salvador 2024 Sessions

solaci - 0
Review the highlights of the XLIX SOLACI Regional Sessions held at the Intercontinental Hotel in San Salvador, El Salvador between November 7 and 8,...

The El Salvador 2024 Sessions are coming soon

solaci - 0
The XLIX SOLACI 2024 Regional Sessions (17th Central America & the Caribbean) are approaching, and will take place in the city of San Salvador (El Salvador)....

Check out the best images of the Arequipa 2024 Sessions

solaci - 0
Review the highlights of the XVIII SOLACI Regional Sessions held at the Hanan Hotel in Arequipa, Peru between October 3 and 4, 2024. <!-- wp:tw/bwg...

Access

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Terms of Use -Privacy Policy